Welcome to our dedicated page for Reviva Pharmaceuticals Holdings news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceuticals Holdings stock.
Reviva Pharmaceuticals Holdings, Inc. (symbol: RVPH) is a late-stage pharmaceutical company based in San Jose, California. Located at 5941 Optical Ct, the company is renowned for discovering, developing, and seeking to commercialize innovative therapeutics for various diseases. Their primary focus areas include the central nervous system, inflammatory, and cardiometabolic diseases.
Leveraging a unique chemical genomics-driven technology platform and proprietary chemistry, Reviva aims to revolutionize treatment options. Their pipeline currently includes two prominent drug candidates:
- Brilaroxazine (RP5063): This versatile drug is intended to address multiple neuropsychiatric conditions such as schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis.
- RP1208: Another promising candidate in their pipeline.
Reviva Pharmaceuticals continues to make strides with recent achievements and ongoing projects that keep the company at the forefront of medical innovation. For more detailed and up-to-date information, please visit their website or contact their corporate and investor relations representatives.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) will host a webinar on May 2, 2023, at 11:00 AM ET featuring KOL Larry Ereshefsky, PharmD, discussing brilaroxazine (RP5063), a serotonin-dopamine modulator in late development for schizophrenia. The event will cover the unmet medical need in schizophrenia treatment and Reviva's clinical trial data, including the ongoing RECOVER Phase 3 trial. Brilaroxazine has exhibited significant efficacy in a Phase 2 study, demonstrating improvements in PANSS total scores and meeting safety endpoints. Furthermore, it has potential for use in other neuropsychiatric and pulmonary conditions, having received Orphan Drug Designation from the FDA for certain indications. This webinar aims to provide insights on the treatment landscape and sustainable advancements in psychiatric and inflammatory therapies.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced that its Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will present a poster at the 78th Annual Scientific Convention of the Society of Biological Psychiatry from April 27-29, 2023, in San Diego, CA. The presentation, titled "Brilaroxazine (RP5063), a novel serotonin-dopamine stabilizer, displays antipsychotic efficacy in rodents," will take place on April 29, 2023, from 5:00-7:00 PM PT.
Brilaroxazine is a drug candidate showing significant clinical promise for treating schizophrenia and related disorders. In Phase 2 studies, it met primary endpoints, demonstrating efficacy with no adverse effects on weight or metabolic parameters. Additionally, it has potential applications in pulmonary diseases like PAH and IPF, having received Orphan Drug Designation from the FDA. Reviva aims to pursue further development of brilaroxazine for various neuropsychiatric conditions.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) will feature on The RedChip Money Report® on Bloomberg TV on April 22, 2023, at 7 p.m. ET. The interview includes insights from CEO Laxminarayan Bhat regarding the Company’s Phase 3 trial for schizophrenia and promising safety and efficacy results from the Phase 2 study. Reviva’s focus is on developing next-generation therapeutics to address unmet medical needs, with ongoing research on drug candidates like brilaroxazine (RP5063) and RP1208. Reviva holds composition of matter patents for both candidates in the U.S. and Europe. The RedChip Money Report® aims to provide investors with valuable information on small-cap investing and features various financial insights.
FAQ
What is the current stock price of Reviva Pharmaceuticals Holdings (RVPH)?
What is the market cap of Reviva Pharmaceuticals Holdings (RVPH)?
What does Reviva Pharmaceuticals Holdings, Inc. specialize in?
Where is Reviva Pharmaceuticals Holdings, Inc. located?
What is Brilaroxazine (RP5063)?
What is the focus of Reviva's current pipeline?
What technology does Reviva use for drug development?
Who can be contacted for more information about Reviva Pharmaceuticals?
What other drug candidate is in Reviva's pipeline besides Brilaroxazine?
What are the therapeutic areas targeted by Reviva Pharmaceuticals?
How can I stay updated with Reviva Pharmaceuticals' latest news?
Who is the main contact for investor inquiries at Reviva Pharmaceuticals?
